These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 21922752

  • 1. [Current progress in the development of mucosal vaccines].
    Takeyama N, Yuki Y, Kiyono H.
    Nihon Rinsho; 2011 Sep; 69(9):1555-60. PubMed ID: 21922752
    [Abstract] [Full Text] [Related]

  • 2. New generation of mucosal adjuvants for the induction of protective immunity.
    Yuki Y, Kiyono H.
    Rev Med Virol; 2003 Sep; 13(5):293-310. PubMed ID: 12931340
    [Abstract] [Full Text] [Related]

  • 3. New perspectives in vaccine development: mucosal immunity to infections.
    McGhee JR, Kiyono H.
    Infect Agents Dis; 1993 Apr; 2(2):55-73. PubMed ID: 8162356
    [Abstract] [Full Text] [Related]

  • 4. [Development of oral vaccines].
    Matsubara A, Shimizu Y, Karamatsu K, Yasutomi Y.
    Nihon Rinsho; 2008 Oct; 66(10):1873-8. PubMed ID: 18939484
    [Abstract] [Full Text] [Related]

  • 5. [The development of mucosal vaccines].
    Bakke H, Haneberg B.
    Tidsskr Nor Laegeforen; 2006 Nov 02; 126(21):2818-21. PubMed ID: 17086224
    [Abstract] [Full Text] [Related]

  • 6. [Mucosal immune system and mucosal vaccine].
    Yanagita M, Hiroi T, Kiyono H.
    Nihon Rinsho; 1997 Feb 02; 55(2):492-501. PubMed ID: 9046845
    [Abstract] [Full Text] [Related]

  • 7. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.
    Virology; 2008 Oct 25; 380(2):412-20. PubMed ID: 18786689
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In defense of mucosal surfaces. Development of novel vaccines for IgA responses protective at the portals of entry of microbial pathogens.
    McGhee JR, Mestecky J.
    Infect Dis Clin North Am; 1990 Jun 25; 4(2):315-41. PubMed ID: 2189002
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Delivery systems: a vaccine strategy for overcoming mucosal tolerance?
    Mann JF, Acevedo R, Campo JD, Pérez O, Ferro VA.
    Expert Rev Vaccines; 2009 Jan 25; 8(1):103-12. PubMed ID: 19093777
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
    De Magistris MT.
    Adv Drug Deliv Rev; 2006 Apr 20; 58(1):52-67. PubMed ID: 16516335
    [Abstract] [Full Text] [Related]

  • 16. Mucosal vaccination and therapy with genetically modified lactic acid bacteria.
    Wells J.
    Annu Rev Food Sci Technol; 2011 Apr 20; 2():423-45. PubMed ID: 22129390
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Vaccines against mucosal infections.
    Holmgren J, Svennerholm AM.
    Curr Opin Immunol; 2012 Jun 20; 24(3):343-53. PubMed ID: 22580196
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.